With a lack of quality data on this already neglected tropical disease, presenting evidence-based advocacy to convince policy-makers of the need for greater action around snakebite is no easy task. As part of our Snakebite Project, HAI is developing a much-needed evidence base on snakebite incidence rates and the price, the community and health system response, and the availability and affordability of antivenom in Kenya and Uganda by gathering data from healthcare facilities and communities.


Access to snakebite envenoming and internationally controlled essential medicines (ICEMs) are both global issues that affect low- and middle-income countries significantly. In this lecture delivered to students at Vrije Universiteit Amsterdam as part of their course on “Double Burden of Disease”, Ben Waldmann and Gaby Ooms focused on what ICEMs are, the treatment gap, barriers to access, as well as Health Action International’s (HAI) response in this area. They also discussed snakebite, including its global burden, the link to antivenom access, our research from the field in Kenya and HAI’s response on all levels.



Report Snakebite in Kenya: Evidence from the Field | Research data from 2019-2020

Research Findings
Fact Sheets